Director/PDMR Shareholding

Renalytix PLC

01 October 2026

 

Renalytix plc

(“Renalytix” or the “Company”)

Director/PDMR Dealing

LONDON and NEW YORK, 1 October 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 29 September 2026, certain investment vehicles connected with Christopher Mills, Non-Executive Director, have completed the purchase of 1,166,667 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.06 per Ordinary Share.

Following completion of this purchase, Christopher Mills and the investment vehicles connected with him are interested in 18,201,690 Ordinary Shares representing 2.7% of the issued share capital of the Company, as enlarged by the recent equity placing.

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker)		Tel: [phone]
David Hignell / Jen Clarke (Corporate Finance)
Vadim Alexandre (Corporate Broking)
Oberon Capital (Joint Broker)	Tel: [phone]
Mike Seabrook / Nick Lovering
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom’s medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare-reimbursed prognostic tool capable of understanding a patient’s risk with diabetic kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Harwood Capital LLP*
2	Reason for the notification
a)	Position/status	Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.0025 each
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Sale of Ordinary Shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.06	1,166,667
d)	Aggregated information
	- Aggregated volume	1,166,667
	- Price	£0.06
e)	Date of the transaction	29 September 2026
f)	Place of the transaction	London Stock Exchange, AIM

*Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher's shareholding is made up of ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, Oryx International Growth Fund Limited and Harwood Capital LLP.

 

END